Bradley Pharmaceuticals Skin Cancer Screening Tour Encourages Visits To Dermatologists

Bradley
Pharmaceuticals, Inc. (NYSE: BDY) is encouraging everyone to visit their
dermatologist for skin cancer screening as the summer season begins.
Bradley's Doak Dermatologics subsidiary, in partnership with The Skin
Cancer Foundation, established The Skin Cancer Screening Tour last year and
has been providing complimentary screenings for the general public
throughout the country. Almost 7,000 individuals were screened since the
Tour started in March 2006.



The Tour stops at cities throughout the U.S. where local,
board-certified dermatologists perform free skin cancer evaluations in a
38-foot Mobile Diagnosis Vehicle (MDv) that was designed and built by Doak
Dermatologics. The Tour actively promotes skin cancer awareness and reminds
the general public about the importance of visiting their dermatologist for
early detection and treatment of skin cancers. Skin cancer is often curable
if diagnosed and treated early enough.



Since last year, the Tour visited 47 cities and identified more than
2,000 individuals as requiring further medical attention for a precancerous
or cancerous condition. Over 1,400 individuals were identified with actinic
keratosis, the most common type of precancerous skin lesion that affects
1.3 million people annually. Physicians also detected 165 individuals with
squamous cell carcinoma, a fast growing form of skin cancer that affects
200,000 people each year, and 538 individuals with basal cell carcinoma,
which affects more than 800,000 annually. Melanoma, the most serious form
of skin cancer, was detected in 59 individuals.



According to the American Cancer Society, more than one million new
cases of skin cancer will be diagnosed in the United States this year and
one in five Americans will develop some form of skin cancer during their
lifetime. Invasive melanoma is the sixth most common cancer in men and
women and the second most common cancer in women aged 20-29 years old.



"We are extremely proud of how successful the Tour is, and are thankful
to all the physicians who provided complimentary skin cancer screenings to
thousands of individuals. Also, we raised considerable public awareness
about the need to visit a dermatologist for early skin cancer detection,"
stated Daniel Glassman, President and CEO of Bradley Pharmaceuticals.
"Since more than one million people will be diagnosed with skin cancer this
year, annual screening is an important part of a complete health regimen.
As the summer begins, more individuals will engage in outdoor activities
and be exposed to sunlight. We encourage everyone to visit their
dermatologist and be screened this year."



To learn more about The Skin Cancer Screening Tour and find a list of
upcoming events, please visit skincancerscreeningtour, or the
Bradley Pharmaceuticals website at: bradpharm.
















Bradley Pharmaceuticals common stock is listed on the NYSE under BDY.



Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty
pharmaceutical company and markets to niche physician specialties in the
U.S. and international markets. Bradley's success is based upon its core
strengths in marketing and sales which enables the company to Commercialize
brands that fill unmet patient and physician needs; Develop new products
through life cycle management; and In-License phase II and phase III drugs
with long-term intellectual property protection that upon approval leverage
Bradley's marketing and sales expertise to increase shareholder value.
Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in
therapies for dermatology and podiatry; Kenwood Therapeutics, providing
gastroenterology, OB/GYN, respiratory and other internal medicine brands;
and A. Aarons, which markets authorized generic versions of Doak and
Kenwood therapies.



Important announcements:



Bradley Pharmaceuticals will present at the Banc of America Securities
Health Care Conference 2007, to be held at The Four Seasons Hotel in Las
Vegas, Nevada, May 30, 2007.



Bradley Pharmaceuticals will present at the FTN Midwest Securities
Health Care Conference 2007, to be held at the Four Seasons Hotel in New
York, NY, June 5, 2007.



Safe Harbor for Forward-Looking Statements



This release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or
developments that Bradley expects, believes or anticipates will or may
occur in the future. Forward-looking statements are subject to numerous
risks and uncertainties, many of which are beyond Bradley's control. Actual
results may differ materially from those projected. These risks and
uncertainties include those described from time to time in Bradley's SEC
filings, including its Annual Report on Form 10-K and its most recent
Quarterly Report on Form 10-Q. Except as required by law, Bradley
undertakes no obligation to publicly update any forward-looking statement
in this press release, whether as a result of new information, future
events or otherwise.


Bradley Pharmaceuticals, Inc.

bradpharm